Serum  JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients

Petrusel, Livia; Ilieș, Maria; Leucuţa, Daniel; Rusu, Ioana; Seicean, Andrada; Iuga, Cristina; Seicean, Radu

doi:10.14715/cmb/2021.67.3.14

Cited by 3 publications

(1 citation statement)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is an essential factor involved in the STAT 3/JAK2 pathway related to the inflammatory status of pancreatic ductal adenocarcinoma (19). IL-8 can promote the recruitment and activation of tumorrelated bodies, releasing inflammatory and pain mediators (20,21). In addition, IL-8 can directly act on surrounding neurons, causing the generation and transmission of pain signals (22).…”

Section: Discussionmentioning

confidence: 99%

- Mechanism of LDH and IL-8 Involved in pancreatic cancer Pain and the Correlation of Pain Degree

2024

J Med Biochem

View full text Add to dashboard Cite

Objective: To observe the mechanism of lactate dehydrogenase (LDH) and interleukin 8 (IL-8) in pancreatic cancer pain and their correlation with pain degree. Methods: 126 patients with pancreatic cancer who visited our hospital from January 2021 to February 2023 were selected. The patients were divided into 58 patients with low pain (1~3 points) and 68 patients with high pain (4~10 points) by visual analog scale (VAS). And 50 health examinees in the same period were selected as the healthy control group. The serum LDH and IL-8 concentrations are analyzed by enzyme-linked immunosorbent assay, as well as the subjective pain grading method scoreis analyzed. The differences in LDH and IL-8 concentrations among the three groups of patients were compared. Pearson correlation analysis was used to investigate the correlation between LDH, IL-8 concentrations and patient pain. Binary logistic regression was used to determine independent risk factors for high pain, and ROC curves were used to analyze the diagnostic efficacy of each indicator. Result: The serum LDH and IL-8 concentrations in the high pain group were exceed the low pain group’s (P<0.05). The serum LDH and IL-8 concentrations in the low pain groupexceed the healthy control group’s(P<0.05). Pearson correlation analysis revealed a positive correlation between serum LDH concentration and pain grading (r=0.736, P=0.000). The serum IL-8 has positive correlation with pain grading (r=0.680, P=0.000). Serum LDH and IL-8 concentrations have positive correlation(r=0.589, P=0.000). LDH and IL-8 concentrations are independent risk factors for high pain levels (OR=1.033, 1.142, P<0.05). The logistic regression prediction model formula was used: Y=constant+B1X1+B2X2+...+BnXn to set the joint diagnostic prediction model as -12.063+0.033×LDH+0.133×IL-8. The areas under the ROC curves of LDH, IL-8, and predictive model (LDH+IL-8) in patients with high pain were 0.925, 0.945, and 0.974, respectively. The relevant standards for LDH are>190U/L, IL-8 is>36pg/mL, and the relevant standards for prediction models are>5.75. Conclusion: LDH and IL-8 participate in the pain aggravation process of pancreatic cancer, and are closely related to the pain grading. The combination of LDH and IL-8 can be used as a biological indicator to evaluate the pain severity of pancreatic cancer, and provide reference for clinical diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

- Mechanism of LDH and IL-8 Involved in pancreatic cancer Pain and the Correlation of Pain Degree

2024

J Med Biochem

View full text Add to dashboard Cite

show abstract

STAT3 signaling in pancreatic ductal adenocarcinoma: a candidate therapeutic target

Al-Hetty

Abdulameer

Alkubaisy

et al. 2023

Pathology - Research and Practice

View full text Add to dashboard Cite

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer

Rizwi

Abubakar

Puppala

et al. 2023

J Environ Pathol Toxicol Oncol

View full text Add to dashboard Cite

According to the World Health Organization (WHO), cancer is the second-highest cause of mortality worldwide, killing nearly 9.6 million people annually. Despite the advances in diagnosis and treatment during the last couple of decades, it remains a serious concern due to the limitations of currently available cancer management strategies. Therefore, alternative strategies are highly required to overcome these glitches. In addition, many etiological factors such as environmental and genetic factors initiate the activation of the Janus kinase (JAK)-signal transducer and activator of the transcription (STAT) pathway. This aberrant activation of the JAK-STAT pathway has been reported in various disease states, including inflammatory conditions, hematologic malignancies, and cancer. For instance, many patients with myeloproliferative neoplasms carry the acquired gain-of-function JAK2 V617F somatic mutation. This knowledge has dramatically improved our understanding of pathogenesis and has facilitated the development of therapeutics capable of suppressing the constitutive activation of the JAK-STAT pathway. Our aim is not to be expansive but to highlight emerging ideas towards preventive therapy in a modern view of JAK-STAT inhibitors. A series of agents with different specificities against different members of the JAK family of proteins is currently undergoing evaluation in clinical trials. Here we give a summary of how JAK-STAT inhibitors function and a detailed review of current clinical drugs for managing cancer as a new therapeutic approach.

show abstract

Serum JAK/STAT profile is related to the IL expression but not with the outcome in pancreatic adenocarcinoma patients

Cited by 3 publications

References 40 publications

- Mechanism of LDH and IL-8 Involved in pancreatic cancer Pain and the Correlation of Pain Degree

- Mechanism of LDH and IL-8 Involved in pancreatic cancer Pain and the Correlation of Pain Degree

STAT3 signaling in pancreatic ductal adenocarcinoma: a candidate therapeutic target

Janus Kinase-Signal Transducer and Activator of Transcription Inhibitors for the Treatment and Management of Cancer

Contact Info

Product

Resources

About